Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors—A Retrospective Study

Christine Neuchel1,2, Daniel Fürst1,2, Dietger Niederwieser3, Donald Bunjes4, Chrysanthi Tsamadou1,2, Gerald Wulf5, Michael Pfreundschuh6, Eva Wagner7, Gernot Stuhler8, Hermann Einsele9, Hubert Schrezenmeier1,2, Joannis Mytilineos1,2,10*

1 Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Württemberg–Hessen and University Hospital of Ulm, Ulm, Germany, 2 Institute of Transfusion Medicine, University of Ulm, Ulm, Germany, 3 Department of Hematology/Oncology, University of Leipzig, Leipzig, Germany, 4 Department of Hematology/Oncology, University Clinic Ulm, Ulm, Germany, 5 Department of Hematology/Oncology, Georg-August-University Göttingen, Göttingen, Germany, 6 Department of Internal Medicine I, Universitätsklinikum des Saarlandes, Homburg, Germany, 7 Department of Medicine III, Johannes Gutenberg-University Mainz, Mainz, Germany, 8 Centre for Bone Marrow and Blood Stem Cell Transplantation, Deutsche Klinik für Diagnostik, Wiesbaden, Germany, 9 Department of Medicine II, University Hospital Würzburg, Würzburg, Germany, 10 DRST—German Registry for Stem Cell Transplantation, Essen, Germany

j.mytilineos@blutspende.de

Abstract

Natural Killer cells (NK) are lymphocytes with the potential to recognize and lyse cells which escaped T-cell mediated lysis due to their aberrant HLA expression profiles. Killer cell immunoglobulin-like receptors (KIR) influence NK-cell activity by mediation of activating or inhibitory signals upon interaction with HLA-C (C1, C2) ligands. Therefore, absence of ligands for donor inhibitory KIRs following hematopoietic stem cell transplantation (HSCT) may have an influence on its outcome. Previous studies showed that C1 negative patients have a decreased HSCT outcome. Our study, based on a cohort of 200 C1-negative patients, confirmed these findings for the endpoints: overall survival (OS: HR = 1.41, CI = 1.14–1.74, p = 0.0012), disease free survival (DFS: HR = 1.27, CI = 1.05–1.53, p = 0.015), treatment related mortality (TRM: HR = 1.41, CI = 1.01–1.96, p = 0.04), and relapse incidence (RI: HR = 1.33, CI = 1.01–1.75, p = 0.04) all being inferior when compared to C1-positive patients (n = 1246). Subsequent analysis showed that these findings applied for patients with myeloid malignancies but not for patients with lymphoproliferative diseases (OS: myeloid: HR = 1.51, CI = 1.15–1.99, p = 0.003; lymphoblastic: HR = 1.26, CI = 0.91–1.75, p = 0.16; DFS: myeloid: HR = 1.31, CI = 1.01–1.70, p = 0.04; lymphoblastic: HR = 1.21, CI = 0.90–1.61, p = 0.21; RI: myeloid: HR = 1.31, CI = 1.01–1.70, p = 0.04; lymphoblastic: HR = 1.21, CI = 0.90–1.61, p = 0.21). Interestingly, within the C1-negative patient group, transplantation with KIR2DS2 resulted in better OS (9/10 matched: HR = 0.24, CI = 0.08–0.67, p = 0.007) as well as DFS (9/10 matched: HR = 0.26, CI = 0.11–0.60, p = 0.002), and transplantation with KIR2DS1 positive donors was associated with a decreased RI (HR = 0.30, CI = 0.13–0.69, p = 0.005). TRM was increased when the donor was positive for KIR2DS1 (HR = 2.61, CI = 1.26–5.41,
are available on-site at our institute for individuals who meet the criteria for access to confidential patient data. Please contact Dr. Joannis Mytilineos (mj.ytillineos@blutspende.de) to request access to confidential data.

Funding: This work was funded by the Deutsche José Carreras Leukämie-Stiftung e.V. (Grant No. DJCLS 11/10) (https://www.carreras-stiftung.de) and the German Red Cross Blood Transfusion Service, Baden-Württemberg – Hessen (http://www.blutspende.de/en/home/home.php). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist

Abbreviations: AL, Unclassified acute leukemia; ALL, Acute lymphoblastic leukemia; AML, Acute myeloid leukemia; CI, Confidence interval; CLL, Chronic lymphoblastic leukemia; CML, Chronic myeloid leukemia; DFS, Disease free survival; GvHD, Graft-versus-host disease; GvL, Graft-versus-leukemia; HLA, Human Leukocyte Antigen; HR, Hazard ratio; HSCT, Hematopoietic stem cell transplantation; KIR, Killer cell immunoglobulin-like receptors; MDS, Myelodysplastic syndrome; MM, Multiple myeloma; NK, Natural Killer cell; OS, Overall survival; RI, Relapse incidence; SBT, sequence based typing; TRM, Treatment related mortality.

Introduction

Haematopoietic stem cell transplantation (HSCT) has been established as a potentially curative treatment for a variety of haematologic diseases. However, malignancy relapse after HSCT remains the most frequent cause of treatment failure[1]. Therefore, introduction of a T-cell mediated graft-versus-leukemia (GvL) effect is of great importance for a successful treatment [2]. Unfortunately, there are downsides to this T-cell alloreactivity as it is associated with graft-versus-host disease (GvHD)[3;4] which is a major complication following HSCT. Furthermore, transformed cells may escape T-cell mediated lysis by down regulation of the Human Leukocyte Antigen (HLA) expression on their cell surface[5–7]. On the other hand, Natural Killer cells (NK) are lymphocytes that have the potential to recognize and lyse cells with aberrant HLA-expression profiles, thereby mediating a GvL-effect of their own. It has been suggested that this competence qualifies NK cells to conduct an anti-leukemic immune response without causing a detrimental GvHD[8;9]. The functions of NK cells are controlled by interactions between NK cell receptors and ligand molecules on the respective target cells. NK cell targeting of leukemic cells is facilitated, among others, by the communication between killer cell immunoglobulin-like receptors (KIR) on the surface of NK cells and HLA-A, -B, -C molecules on the surface of leukemic cells[10–12]. The KIR gene locus is characterized by high complexity, as it shows a high genetic variation in regard of receptor functions (activation or inhibition of target cell killing), gene content, copy number variation, and sequence polymorphism[13]. KIR expression profiles are further classified into two distinct haplotypes, A and B, based on the presence or absence of certain KIR genes[14;15]. The A-haplotype is defined by the presence of the two inhibitory KIRs KIR2DL1 and KIR2DL3, and KIR2DS4 as sole activating KIR. The B-haplotype is characterized by the presence of a variety of different combinations of KIR genes, however, the presence of at least one of the KIRs KIR2DL5, KIR2DS1/2/3/5, or KIR3DS1 is mandatory.

Possibly, the most important KIR-ligand interaction is that between HLA-C antigens and their corresponding KIRs, in which both, inhibitory and activating, receptors are involved[16]. However, HLA-C/KIR interactions appear to be even more complex, given that HLA-C antigens are divided into two ligand groups based on specific amino acid residues[17]: Antigens in the C1 group bear an asparagine residue on position 80 and interact with inhibitory KIR2DL2 and KIR2DL3 as well as activating KIR2DS2, whereas C2 group ligands carry a lysine residue at position 80 and interact with inhibitory KIR2DL1 and activating KIR2DS1 ([18;19]. Activating signals and missing inhibition, both, lead to lysis of target cells[20;21]. Lack of interaction between a KIR and its respective HLA-C ligand in conjunction with activating signals may induce lysis of the target cell, a mechanism which is known as “missing self-recognition”[22]. In fact, absence of one or more ligands for donor inhibitory KIRs in patients with acute myeloid leukemia (AML) was shown to have a positive effect on HSCT outcome in haploidentical transplantations[20;23]. Whereas this model is still controversially discussed in the context of matched HSCT[24–26], it has been shown that in matched unrelated transplantation the presence or absence of C1 and/or C2 ligands significantly affects outcome: patients who expressed at least one C1 ligand showed superior overall survival and lower TRM rates than patients who were homozygous for the C2 ligand[27].
In this multicentre study, we evaluated the C-ligand impact on unrelated HSCT outcome in a large cohort of 1446 KIR & 5-loci-high resolution HLA-typed HSCT transplant pairs and thereby confirmed the C1-ligand negative patient cohort to be at higher risk than C1-positive patients. However, the incidence of patient C2 homozygosity is relatively low (in our cohort 14%). Transplantation with KIR B-haplotype positive donors has already been shown to increase HSCT success [28–31]. KIR haplotype analyses that were performed in our lab confirm the beneficial effect of donor KIR B-haplotype on transplantation outcome (Abstract published in Biology of blood and marrow transplantation in 2015 [32]). NK cells and their activating KIR molecules have also been shown to play a beneficial role in the immune response against various infectious agents [33–35] as well as in the killing of T-cell blasts [36] and the prevention of leukaemia relapse [37].

KIR-Haplotype organisation, however, unveiled highly various phenotypes, especially among individuals with KIR B-Haplotypes. In order to analyse the relative contribution of individual B-Haplotype defining KIRs on HSCT outcome, sub-analyses on the level of single KIR genes are required. In this study, we aimed to examine if C1-ligand negative patients, who were found to be at risk post transplantation, could benefit from transplantations carried out from donors with various activating KIRs.

**Patients and Methods**

**Study cohort**

The study population included a total of 1446 patients transplanted for malignant disorders with T-cell repleted grafts from unrelated donors between 2000 and 2009. Benign diseases of the hematopoietic system as well as inborn genetic diseases were excluded. Patients with AML (acute myeloid leukemia), ALL (acute lymphoblastic leukemia), AL (unclassified acute leukemia), CML (chronic myeloid leukemia), CLL (chronic lymphoblastic leukemia), MDS (myelodysplastic syndrome), and MM (multiple myeloma) were eligible. Disease stages were adopted from a previous report published by the European Society for Blood and Marrow Transplantation (EBMT) study group [38]: Early disease stage included AML, AL, and ALL transplanted in first complete remission, CML in first chronic phase, and NHL, MM, and MDS transplanted either untreated or in first complete remission. Intermediate disease stage was defined as AML, ALL, or NHL in second complete remission or first relapse, AL transplanted in second complete remission, lymphoma and MM in second complete remission, partial remission or stable disease, CML at all other stages than first chronic phase or blast crisis, and MDS in second complete remission or in partial remission. Advanced stage was assigned to AML, AL, ALL, and MDS in all other disease phases, CML in blast crisis, and lymphoma and MM in all other disease stages than early or intermediate.

Graft source was either peripheral blood stem cells or bone marrow. Only first allogeneic transplantations were included in the analysis. Transplant pairs were either 10/10 matched or single HLA-A, -B, or -C mismatched. All patients received myeloablative or reduced intensity conditioning. Myeloablative conditioning regimen was defined according to the EBMT recommendations as treatment with total body irradiation equal or above 10 Gy and/or cyclophosphamide equal or greater than 120 mg/m², and/or busulfan equal or greater than 16 mg/kg [39;40]. Treatment with less intense regimen was classified as reduced intensity conditioning. All patients received T-cell replete grafts. Written recipient and donor consents for HLA typing and for the analysis of clinical data were obtained. Clinical data was provided by the German Registry for Stem Cell Transplantation (DRST) in pseudonymised form. This data was collected by the transplant centers at day 100 post transplantation and yearly thereafter, according to the EBMT guidelines. The study was approved by the ethical review board of the University of Ulm (project number 263/09). Overall survival (OS) was defined as time to death...
from any cause and was censored at the time of last follow-up. Disease-free survival (DFS) was defined as time to relapse of primary malignancy, or death from any cause, and was also censored at the time of last follow-up. Relapse incidence (RI) was defined as occurrence of relapse of hematologic malignancy at any given time point. Treatment-related mortality (TRM) was defined as mortality in complete disease remission.

**HLA-Typing in patients and donors**

Donor-recipient pairs from unrelated donor searches completed before May 2005 were low resolution typed for HLA-A and -B, and high resolution typed for HLA-DRB1 and -DQB1. Stored DNA material of these individuals was retrospectively high resolution typed for HLA-A, -B, and -C. For unrelated donor searches which were initiated after 05/2005 5-loci high resolution HLA-typing was carried out upfront.

High resolution HLA-typing was performed by sequence based typing (SBT) using a CE-certified in-house Kit for HLA-class I (H-Seq-ABC, DRK-BSD Baden- Württemberg–Hessen gGmbH, Frankfurt am Main, Germany) and by in-house SBT (H-Seq-DR, DRK-BSD Baden-Württemberg–Hessen gGmbH, Frankfurt am Main, Germany and H-Seq-DQB, DRK-BSD Baden-Württemberg–Hessen gGmbH, Frankfurt am Main, Germany) or Luminex® (Life Technologies, Carlsbad, CA, USA) PCR-sequence specific oligonucleotide probe (PCR-SSO) method for HLA-class II. Exons 2 and 3 were sequenced for HLA-class I typing, and exon 2 was analysed for HLA-class II testing. Additional typing for relevant non-expressed alleles was performed according to the National Marrow Donor Program confirmatory typing requirements[41].

**KIR-Typing in patients and donors**

KIR-typing was performed using the commercially available "KIR Genotyping SSP Kit" from Thermo Fisher Scientific (Waltham, MA, USA). The Kit uses sequence specific primer PCR to assign presence or absence, respectively, of a given KIR gene. The method allows the identification of the following KIR-genes: KIR2DL1/2/3/4/5A/5B, KIR2DS1/2/3/4/5, KIR3DL1/2/3, KIR3DS1, KIR2DP1, and KIR3DP1.

| Table 1. General patient characteristics. |
|-----------------------------------------|
| **Age** | **n** | **%** | **Disease stage** | **n** | **%** | **Patient and donor sex combination** | **n** | **%** |
| 18–40 | 359 | 24.8% | Early | 556 | 38.5% | Donor female, patient male | 162 | 11.2% |
| 41–60 | 1071 | 74.1% | Intermediate | 518 | 35.8% | Others | 1284 | 88.8% |
| 61–76 | 16 | 1.1% | Advanced | 372 | 25.7% | Conditioning | |
| HLA-compatibility | Graft source | | Bone Marrow | 91 | 6.3% | Myeloablative | 870 | 39.8% |
| 9/10 | 1022 | 70.7% | Peripheral Blood stem cells | 1355 | 93.7% | Reduced intensity | 576 | 60.2% |
| Year of transplantation | Diagnosis myeloid | | Diagnosis lymphoblastic | | | | | |
| 2000–2005 | 377 | 26.1% | AML | 447 | 30.9% | ALL | 189 | 13.1% |
| 2006–2009 | 1069 | 73.9% | CML | 65 | 4.5% | CLL | 82 | 5.7% |
| | | | MDS | 271 | 18.7% | MM | 131 | 9.1% |
| | | | NHL | | | | 176 | 12.2% |
| | | | Diagnosis other | | | | AL | 85 | 5.9% |

doi:10.1371/journal.pone.0169512.t001
Assessment of missing KIR ligand status

KIR ligand status of patients was obtained from high resolution HLA-typing. HLA-C molecules were grouped according to the presence of epitopes recognized by KIRs: HLA-C antigens with an asparagine residue at amino acid sequence position 80 possess the C1 epitope, which acts as ligand for the inhibitory KIR2DL2 and KIR2DL3 as well as for the activating KIR2DS2. Accordingly, HLA-C antigens with a lysine residue at this position possess the C2 epitope, which acts as ligand for the inhibitory KIR2DL1 as well as for the activating KIR2DS1.

The absence of C1 or C2 in patients who were transplanted with a KIR2DL2/3 or KIR2DL1 positive donor, respectively, was considered as “missing ligand”. Control patient groups carried at least one ligand for any donor KIR2DL1 or KIR2DL2/3, respectively.

Statistical analysis

All statistical analyses were performed using the open source program for statistical computing “R”, version 3.0.2. Cumulative estimates of overall survival (OS) and disease free survival (DFS) were obtained using Kaplan-Meier analysis. Extended Cox regression models allowing for time-dependent covariates were used to conduct multivariate analyses of OS and DFS. Univariate analyses of relapse incidence (RI) and treatment related mortality (TRM) were performed using competing risk analysis. Competing risk regression models for stratified data were used for multivariate analysis of RI and TRM. The categorical variable diagnosis showed different baselines of hazard for the respective patient sub-groups. Hence, for both multivariate models stratification for diagnosis was accomplished rather than integrating diagnosis as a covariate [42;43]. Centre effects were adjusted using a gamma frailty term (fitted with the R-package “survival”) [44;45]. A stepwise backward exclusion procedure was used for model selection, where all variables have been included in the first model and then successively reduced (at each step the least significant) until the loss of information became significant (analysis of missing ligand model p ≤ 0.05; KIR analyses p ≤ 0.01) [43]. In order to address the problem of multiple testing and
potentially associated type 1 errors we set the significance level for our KIR analyses to 0.01. Covariates were assessed according to previously published recommendations of the EBMT study group[42;43;46], including patient age, disease stage, graft manipulation, conditioning regimen, graft source, donor source (national vs. international), year of transplantation, time between diagnosis and transplantation, and donor-recipient gender combination. For the clinical

Fig 1. Univariate OS analysis in C1-negative patients (missing C1 ligand) vs. C1-positive patients who were transplanted with KIR2DL2 or KIR2DL3 positive donors. Dashed orange line: C1-negative patients (n = 200). Solid black line: C1-positive patients (n = 1239). p = 0.0014.

doi:10.1371/journal.pone.0169512.g001
covariates analysed, the data was complete. All models were checked for interactions and proportional hazards assumption. No significant interactions between covariates were found and violations of proportional hazards assumption were adjusted by using time dependent covariates.

Fig 2. Univariate DFS analysis in C1-negative patients (missing C1 ligand) vs. C1-positive patients who were transplanted with KIR2DL2 or KIR2DL3 positive donors. Dashed orange line: C1-negative patients (n = 200). Solid black line: C1-positive patients (n = 1239). p = 0.006.

doi:10.1371/journal.pone.0169512.g002
Results

Patient characteristics

General patient characteristics are shown in Table 1. The cohort included 1446 transplant pairs. Median patient age was 52 years. Most patients were in early (38.5%) and intermediate (35.8%) disease state. Stem cell source was peripheral blood stem cells in 93.7% cases. Almost two thirds (60.2%) of the patients received myeloablative conditioning. An unfavourable donor-patient sex mismatch (female donor for a male patient) was found in 11.2% of transplant pairs. Most patients received a graft from a 10/10 matched HLA compatible donor (70.7%), whereas 29.3% were transplanted with a 9/10 matched donor. Median post-transplantation follow-up time was 40 months and maximum follow-up time was 9.5 years.

Table 2 lists the distribution of activating KIR2DS1/2/3/5 and KIR3DS1 among donors subject to subgroups of patients with myeloid or lymphoid malignancies. Between 54 and 60% of donors were positive for KIR2DS1. KIR2DS2 was even more prevalent with up to 75% being carriers. KIR2DS3 and KIR2DS5 were found in 40–50% of donors.

C1-negative patients show significantly inferior HSCT outcome

Distribution of KIR2DL1/2/3 and HLA-C-ligands among patients and donors is shown in Table 3. All individuals in the cohort were either positive for KIR2DL2 or KIR2DL3, or both (approximately 40%). The corresponding C1 ligand for these KIRs was carried in 86% of the individuals. Of these, 40% were C1 homozygous. KIR2DL1 was detected in 96% of patients and donors. The C2 ligand was detected in 60% of the patients. Homozygosity for this ligand was relatively rare with a prevalence of 13.8%.

Patients who did not possess the C1 ligand (i.e. C2 homozygous) showed significantly inferior OS and DFS after 1, 3 and 5 years post transplantation (Fig 1 and Fig 2) when compared to the C1 positive (C1 homozygous or C1C2 heterozygous) control group (OS: 60.7% vs. 49.7%; 47.0% vs. 36.0%; 41.6% vs. 29.2%, p = 0.0014. DFS: 51.1% vs. 40.0%; 37.6% vs. 27.1%; 30.3% vs. 26.6%, p = 0.006; Table 4). C2 Homozygosity also was associated with increased RI and TRM rates as shown in Fig 3 and Fig 4. Multivariate analysis confirmed these results, since OS (HR = 1.41, CI = 1.14–1.74, p = 0.0012), DFS (HR = 1.27, CI = 1.05–1.53, p = 0.015), RI (HR = 1.33, CI = 1.01–1.75, p = 0.04) and TRM (HR = 1.41, CI = 1.01–1.96, p = 0.04) all were negatively affected when the patients did not possess the C1 ligand (Table 4).

A significant impact of the missing ligand model described in previous studies was solely found for myeloid malignancies. The four endpoints were therefore re-analysed in subgroups of patients with myeloid and lymphoblastic diseases, respectively.

The protective effect of C1 could be observed only in the myeloid group (Table 5), where absence of C1 was associated with reduced OS (myeloid: HR = 1.51, CI = 1.15–1.99, p = 0.003; lymphoblastic: HR = 1.26, CI = 0.91–1.75, p = 0.16), reduced DFS (myeloid: HR = 1.31, CI =

---

Table 4. Multivariate analysis of OS, DFS, RI, and TRM in C1-negative patients vs. patients with at least one C1 ligand.

| Endpoint | Cases | HR   | 95% CI      | p   |
|----------|-------|------|-------------|-----|
| OS       | 200   | 1.41 | 1.14–1.74   | 0.0012 |
| DFS      | 200   | 1.27 | 1.05–1.53   | 0.015 |
| RI       | 200   | 1.33 | 1.01–1.75   | 0.04  |
| TRM      | 200   | 1.41 | 1.01–1.96   | 0.04  |

doi:10.1371/journal.pone.0169512.t004
1.01–1.70, p = 0.04; lymphoblastic: HR = 1.21, CI = 0.90–1.61, p = 0.21), and increased RI (myeloid: HR = 1.31, CI = 1.01–1.70, p = 0.04; lymphoblastic: HR = 1.21, CI = 0.90–1.61, p = 0.21).

There were no differences observed for TRM between the myeloid and lymphoblastic subgroups (myeloid: HR = 1.34, CI = 0.85–2.11, p = 0.20; lymphoblastic: HR = 1.27, CI = 0.75–2.16, p = 0.38).

**Fig 3. Univariate RI analysis in C1-negative patients (missing C1 ligand) vs. C1-positive patients who were transplanted with KIR2DL2 or KIR2DL3 positive donors.** Dashed orange line: C1-negative patients (n = 200). Solid black line: C1-positive patients (n = 1239). p = 0.04.

doi:10.1371/journal.pone.0169512.g003
C1-negative patients with myeloid malignancies were thus identified as being at risk and therefore this patient group is referred as such in subsequent analyses.

Fig 4. Univariate TRM analysis in C1-negative patients (missing C1 ligand) vs. C1-positive patients who were transplanted with KIR2DL2 or KIR2DL3 positive donors. Dashed orange line: C1-negative patients (n = 200). Solid black line: C1-positive patients (n = 1239). p = 0.06.

doi:10.1371/journal.pone.0169512.g004
Missing C2-ligand has no effect on HSCT outcome

Missing C2-ligand does not affect HSCT outcome as shown by Kaplan-Meier analysis (Figs 5–8) and multivariate analysis (OS: HR = 0.91, CI = 0.77–1.03, p = 0.22; DFS: HR = 0.94, CI = 0.81–1.09, p = 0.41; RI: HR = 0.97, CI = 0.79–1.19, p = 0.74; TRM: HR = 0.90, CI = 0.69–1.16, p = 0.42).

Transplantation with KIR2DS2 positive donors significantly increases OS and DFS in the C1-negative risk group

Since C1-deficiency was shown to negatively affect HSCT outcome in patients with myeloid, but not lymphoblastic, malignancies, following analyses were conducted in the myeloid patient group, only.

As KIR2DS4 is present in almost all individuals and is expressed on both, A- and B-Haplotypes, this KIR gene was not taken into consideration for any analyses in our study. Additionally, OS and DFS analyses were conducted in subgroups of 10/10 and 9/10 matched transplants.

OS and DFS were significantly improved when the donor was positive for KIR2DS2 and the transplant pair was mismatched at a single HLA-class I gene: The OS rates were twice as high as in the 9/10 matched patient group with a KIR2DS2 negative donor (10/10: 49.5% vs. 44.7%; 38.5% vs. 34.1%; 28.9% vs. 25.6%; 9/10: 57.3% vs. 23.5%; 40.9% vs. 17.6%; Fig 9 and Fig 10). Similarly, donor KIR2DS2 positivity resulted in higher DFS rates in the 9/10 matched patient group (10/10: 40.6% vs. 37.9%; 29.5% vs. 28.4%; 9/10: 51.6% vs. 21.1%; 24.6% vs. 15.8%; Fig 11 and Fig 12). Multivariate analysis confirmed these results (OS: 10/10: HR = 1.02, CI = 0.51–2.07, p = 0.95; 9/10: HR = 0.24, CI = 0.08–0.67, p = 0.007; DFS: 10/10: HR = 1.23, CI = 0.72–2.07, p = 0.44; 9/10: HR = 0.26, CI = 0.11–0.60, p = 0.002; Table 6 and 6B). Reduced intensity conditioning regimen was a significant predictor within our analysis (S1 Table) and it would have been interesting to investigate whether the influence of KIR2DS2 could be observed in both, reduced intensity and myeloablative conditioning, respectively. As individual disease stages (early, intermediate, and advanced) are important predictors for HSCT outcome as well, it would have also been interesting to investigate the effect of donor KIR2DS2 positivity in according to disease stage. Unfortunately the number of cases in our study did not allow these analyses.

Presence of other activating KIR KIR2DS1/3/5 or KIR3DS1 in the donor did not have any effect on OS or DFS (Tables 6 and 7).

Transplantation with KIR2DS1 positive donors is associated with a significantly decreased RI in the C1-negative risk patient group

For RI and TRM analyses, case numbers were too small to conduct sub-analysis in 10/10 and 9/10 matched transplant pairs. Therefore the subsequent analyses of the impact of KIR2DS1/2/
3/5 or KIR3DS1 positive grafts on RI and TRM within the risk patient group were conducted disregarding HLA matching degree (univariate analysis) or with stratification for HLA matching (multivariate analysis).

Transplantation with KIR2DS1 positive donors significantly reduced RI in C1-negative patients (HR = 0.30, CI = 0.13–0.69, p = 0.005) (Fig 13, Table 8). Transplantation with a
KIR2DS2-positive (HR = 1.87, CI = 0.86–4.08, p = 0.12), KIR2DS3-positive (HR = 1.60, CI = 0.83–3.10, p = 0.16), KIR2DS5-positive (HR = 0.37, CI = 0.15–0.92, p = 0.03), or KIR3DS1-positive (HR = 0.51, CI = 0.24–1.10, p = 0.09) donor had no significant effect on RI (Figs 14–16, Table 8).
Transplantation with KIR2DS1 positive donors is associated with a significantly increased TRM in the C1-negative risk patient group.

The results of the multivariate TRM analyses are summarised in Table 9. In the presence of a single HLA class I mismatch, TRM was increased in C1 negative patients who were transplanted with a KIR2DS1 (HR = 2.61, CI = 1.26–5.41, p = 0.001; Fig 17) positive donor.
Transplantation with a KIR2DS5 positive donor had no effect on TRM (HR = 0.81, CI = 0.36–1.86, p = 0.63, Fig 18) and a potential positive effect of a KIR2DS2 positive graft (HR = 0.31, CI = 0.11–0.86, p = 0.03, Fig 19) as well as the effects observed on TRM by selecting a KIR2DS5 (HR = 3.33, CI = 1.20–9.29, p = 0.02), or KIR3DS1 (HR = 2.18, CI = 0.99–4.78, p = 0.05, Fig 20) positive donor, respectively, did not reach the level of statistical significance (0.01).

Fig 8. Univariate TRM analysis in C2-negative (missing C2 ligand) vs. C2-positive patients who were transplanted with KIR2DL1-positive donors. Dashed orange line: C2-negative patients (n = 823). Solid black line: C2-positive patients (n = 558). p = 0.30. doi:10.1371/journal.pone.0169512.g008
The KIR Better/Best model in C1-negative patients

The KIR locus is divided into a centromeric and a telomeric region, each bearing variable KIR gene content motifs designated as cen-A, cen-B, tel-A, and tel-B. The B-motifs contain one or

Fig 9. Univariate OS analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS2 positive donors vs. KIR2DS2 negative donors. Solid black line: donor KIR2DS2-negative. Dashed orange line: donor KIR2DS2-positive. 10/10 matched transplant pairs, donor KIR2DS2-negative (n = 32) vs. donor KIR2DS2-positive (n = 45), p = 0.86.

doi:10.1371/journal.pone.0169512.g009
more of the seven KIR B-haplotype specific genes. It has been shown by Cooley et al, that C1-positive, but not C1-negative patients benefit from transplantation with donors who carry two or more B-motifs. We used the B-content calculator that can be found at http://www.ebi.ac.uk/ipd/kir/donor_b_content.html to assign the donors of our cohort accordingly to one of

Fig 10. Univariate OS analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS2 positive donors vs. KIR2DS2 negative donors. Solid black line: donor KIR2DS2-negative. Dashed orange line: donor KIR2DS2-positive. 9/10 matched transplant pairs, donor KIR2DS2-negative (n = 22) vs. donor KIR2DS2-positive (n = 18), p = 0.04.
three groups based on KIR B-content—neutral (n = 142), better (n = 40) or best (n = 18)—and analysed the impact of this classification on the transplantation outcome of the C1-negative patients. As case numbers in the “best” group were low, we decided to combine the “better” and the “best” donors into the “better/best” group. Multivariate analyses showed that in 9/10
matched transplantations, “better/best” donors may improve DFS (HR = 0.39, CI = 0.15–0.99, p = 0.048), but had no significant effect on OS (HR = 0.69, CI = 0.22–2.21, p = 0.52), RI (HR = 0.48, CI = 0.07–3.29, p = 0.46), or TRM (HR = 0.76, CI = 0.23–2.49, p = 0.65). In 10/10 matched transplant pairs, however, the “better/best” KIR donor status had no effect on
### Table 6. Multivariate analysis of OS in C1-negative patients transplanted with a KIR2DS1/2/3/5 or KIR3DS1 positive donor vs. C1-negative patients transplanted with a KIR2DS1/2/3/5 or KIR3DS1 negative donor.

| Cases | HR   | 95% CI         | p   |
|-------|------|----------------|-----|
| Donor KIR2DS1 negative 10/10 | 47   | 1              | -   |
| Donor KIR2DS1 positive 10/10 | 30   | 0.75           | 0.37–1.52 | 0.42 |
| Donor KIR2DS1 negative 9/10  | 25   | 1              | -   |
| Donor KIR2DS1 positive 09/10  | 15   | 1.88           | 0.74–4.76 | 0.18 |
| Donor KIR2DS2 negative 10/10 | 32   | 1              | -   |
| Donor KIR2DS2 positive 10/10  | 45   | 1.04           | 0.51–2.12 | 0.91 |
| Donor KIR2DS2 negative 9/10  | 22   | 1              | -   |
| Donor KIR2DS2 positive 9/10  | 18   | 0.24           | 0.08–0.67 | 0.007 |
| Donor KIR2DS3 negative 10/10  | 49   | 1              | -   |
| Donor KIR2DS3 positive 10/10  | 28   | 1.38           | 0.68–2.79 | 0.37 |
| Donor KIR2DS3 negative 9/10  | 27   | 1              | -   |
| Donor KIR2DS3 positive 9/10  | 13   | 0.85           | 0.31–2.37 | 0.76 |
| Donor KIR2DS5 negative 10/10  | 56   | 1              | -   |
| Donor KIR2DS5 positive 10/10  | 21   | 0.55           | 0.25–1.24 | 0.15 |
| Donor KIR2DS5 negative 9/10  | 27   | 1              | -   |
| Donor KIR2DS5 positive 9/10  | 13   | 2.19           | 0.78–6.12 | 0.13 |
| Donor KIR3DS1 negative 10/10  | 46   | 1              | -   |
| Donor KIR3DS1 positive 10/10  | 31   | 0.96           | 0.47–1.97 | 0.92 |
| Donor KIR3DS1 negative 9/10  | 26   | 1              | -   |
| Donor KIR3DS1 positive 9/10  | 14   | 1.74           | 0.66–4.56 | 0.26 |

doi:10.1371/journal.pone.0169512.t006

### Table 7. Multivariate analysis of DFS in C1-negative patients transplanted with a KIR2DS1/2/3/5 or KIR3DS1 positive donor vs. C1-negative patients transplanted with a KIR2DS1/2/3/5 or KIR3DS1 negative donor.

| Cases | HR   | 95% CI         | p   |
|-------|------|----------------|-----|
| Donor KIR2DS1 negative 10/10 | 47   | 1              | -   |
| Donor KIR2DS1 positive 10/10 | 30   | 0.65           | 0.38–1.11 | 0.11 |
| Donor KIR2DS1 negative 9/10  | 25   | 1              | -   |
| Donor KIR2DS1 positive 09/10  | 15   | 1.31           | 0.66–2.59 | 0.44 |
| Donor KIR2DS2 negative 10/10 | 32   | 1              | -   |
| Donor KIR2DS2 positive 10/10  | 45   | 1.23           | 0.72–2.07 | 0.44 |
| Donor KIR2DS2 negative 9/10  | 22   | 1              | -   |
| Donor KIR2DS2 positive 9/10  | 18   | 0.26           | 0.11–0.60 | 0.002 |
| Donor KIR2DS3 negative 10/10  | 49   | 1              | -   |
| Donor KIR2DS3 positive 10/10  | 28   | 1.27           | 0.75–2.13 | 0.37 |
| Donor KIR2DS3 negative 9/10  | 27   | 1              | -   |
| Donor KIR2DS3 positive 9/10  | 13   | 0.67           | 0.33–1.37 | 0.27 |
| Donor KIR2DS5 negative 10/10  | 56   | 1              | -   |
| Donor KIR2DS5 positive 10/10  | 21   | 1.14           | 0.64–2.02 | 0.66 |
| Donor KIR2DS5 negative 9/10  | 27   | 1              | -   |
| Donor KIR2DS5 positive 9/10  | 13   | 1.36           | 0.65–2.88 | 0.41 |
| Donor KIR3DS1 negative 10/10  | 46   | 1              | -   |
| Donor KIR3DS1 positive 10/10  | 31   | 0.84           | 0.49–1.45 | 0.54 |
| Donor KIR3DS1 negative 9/10  | 26   | 1              | -   |
| Donor KIR3DS1 positive 9/10  | 14   | 1.24           | 0.62–2.51 | 0.54 |

doi:10.1371/journal.pone.0169512.t007
transplantation outcome (OS: HR = 0.98, CI = 0.46–2.10, p = 0.95; DFS: HR = 1.13, CI = 0.63–2.02, p = 0.69; RI: HR = 1.60, CI = 0.72–3.55, p = 0.25; TRM: HR = 0.80, CI = 0.17–3.80, p = 0.78).

Fig 13. Univariate RI analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS1 positive vs. KIR2DS1 negative donors. Solid black line: donor KIR2DS1 negative. Dashed orange line: donor KIR2DS1 positive. Donor KIR2DS1-negative (n = 72) vs. donor KIR2DS1-positive (n = 45), p = 0.008.

doi:10.1371/journal.pone.0169512.g013
Proposed algorithm for the selection for donors for C1-negative patients

If our findings prove to be correct, and can be confirmed by others, then a possible selection algorithm of donors for C1-negative patients with myeloid malignancies could be as displayed in Fig 21.

Discussion

The missing ligand model is based on the premise that underrepresentation of inhibiting signals will increase donor NK-alloreactivity against remaining malignant cells in the patient. As already described in the results section, all patients and donors within our cohort where positive for at least one inhibitory KIR that binds to HLA-C ligands. These results are consistent with the KIR-frequencies in Caucasoid and German populations provided by allelefrequencies.net[47].

We subsequently investigated if there was any effect of the missing ligand model on unrelated HSCT outcome. Deficiency for the C1-ligand had significantly negative effects on all analysed survival endpoints (OS, DFS, RI, and TRM). In contrast, C2-negative patient status did not affect any of these survival endpoints. Our findings are supported by studies done by Fischer et al.[48] (patients with CML), Giebel et al.[49] (various malignancies), and Hsu et al.[50] (AML and MDS) who also showed a negative impact of patient C1-ligand absence in HSCT outcome. Subsequent analyses confirmed that these findings applied for patients with myeloid malignancies but not for lymphoproliferative diseases. The C1-negative patient group with myeloid malignancies was therefore identified as being at higher risk than C1-positive patients and those with lymphatic diseases. Our findings can be explained by an impaired donor derived NK-cell activity in C1-ligand negative patients. During immune reconstitution the first KIRs to be expressed are KIR2DL2 and KIR2DL3, which recognize C1-ligands[48]. The early onset of donor NK-cells in these patients is consequently non-reactive against C1-ligand negative recipient cells. Furthermore, C1-restricted NK-cells form bigger populations, react faster to interferon γ secretion, and degranulate CD107a more potently than C2-restricted NK cells[51;52]. Additionally, the development of NK-cell activity is dependent on a process called NK-cell licensing which is mediated by interaction with an inhibitory receptor and its ligand[27;53].

Missing inhibition fails NK-cell licensing and therefore the NK-cells remain hypo-responsive. Interestingly, non-licensed NK-cells react extremely hyper-responsive against malignant cells in the early post-transplantation phase[53]. The late occurrence of KIR2DL1 cell surface expression therefore may impair NK-cell activity in two ways: by the failure to take advantage of the hyper-responsive early phase, and by the prolonged hypo-responsiveness thereafter. A further difference between C1-KIR2DL2/3 and

| Table 8. Multivariate analysis of RI in C1-negative patients transplanted with a KIR2DS1/2/3/5 or KIR3DS1 positive donor vs. C1-negative patients transplanted with a KIR2DS1/2/3/5/or KIR3DS1 negative donor. |
|-----------------------------------------------|
| Donor KIR2DS1 negative | 72 | 1 | - | - |
| Donor KIR2DS1 positive | 45 | 0.30 | 0.13–0.69 | 0.005 |
| Donor KIR2DS2 negative | 54 | 1 | - | - |
| Donor KIR2DS2 positive | 63 | 1.87 | 0.86–4.08 | 0.12 |
| Donor KIR2DS3 negative | 76 | 1 | - | - |
| Donor KIR2DS3 positive | 41 | 1.60 | 0.83–3.10 | 0.16 |
| Donor KIR2DS5 negative | 83 | 1 | - | - |
| Donor KIR2DS5 positive | 34 | 0.37 | 0.15–0.92 | 0.03 |
| Donor KIR3DS1 negative | 72 | 1 | - | - |
| Donor KIR3DS1 positive | 45 | 0.51 | 0.24–1.40 | 0.09 |

doi:10.1371/journal.pone.0169512.t008
C2-KIR2DL1 interactions lies within the binding affinity of the receptors to their ligands. Herein, C1-KIR2DL2/3 interactions are considerably weaker than those between C2 and KIR2DL1 [18;51;54;55]. A weak binding affinity may promote overwriting of inhibitory by activating signals and therefore make the NK-cell more potent in killing of malignant cells[18]. The dependence of the observed effect from disease group, however, may be explained by sophisticated defence.
mechanisms of lymphatic blasts against NK-cell activity. CLL-samples have been shown to produce high amounts of tolerogenic HLA-G1 which promotes the acquisition of inhibitory NK cell receptors[56]. Furthermore, CLL and ALL patients show a selective down-regulation of non-Bw4 HLA-molecules (HLA-A and -B molecules with the Bw4 motif are ligands for inhibitory KIR) [6]—a mechanism which impairs both, NK and T-cell activity. The already impaired immune
response against malignant cells therefore seems not to be further influenced by the additional impairment caused by the absence of the C1-ligand.

Transplantation with B-haplotype positive donors has been shown to have beneficial effects on HSCT[28,29]. Since gene content in B-haplotypes is highly variable and the main difference to A-haplotypes is the presence of other activating KIRs than KIR2DS4, we focused our analysis...
on the effects of the remaining activating KIRs on transplantation outcome in the identified risk group. Overall survival and disease free survival were greatly improved upon transplantation with a KIR2DS2-positive donor in the single HLA-class I mismatched setting. Furthermore, again in the presence of a single HLA-class I mismatch, RI was significantly reduced in risk group patients who had received a graft from a KIR2DS1-positive donor when compared to risk group patients who were transplanted with KIR2DS1-negative donor cells. However, transplantation with a donor who carried KIR2DS1, resulted in a higher TRM, respectively. These results are surprising, if one considers that activated NK cells have been shown to mediate graft-versus-leukemia effects (i.e. lower relapse rates) in conjunction with a suppression of graft-versus-host disease (a major cause for higher TRM)[8;9]. Therefore, we expected lower relapse rates without an increase in TRM rates. Given that all patients in our study cohort received T-cell repleted grafts, a T-cell mediated effect may explain these controversial findings. Indeed, it has been shown that activated NK cells are able to directly communicate with CD4 positive T-cells via OX40—OX40 ligand interactions[57] and T-cells which have been activated by OX40 ligand binding have been detected in peripheral inflammatory sites of GvHD[58].

To our knowledge, we are the first to describe a beneficial effect of KIR2DS2 positive donors in HSCT, whereas a beneficial effect of transplantation with KIR2DS1-positive donors has been already described by several study groups[36;37;59]. However, in these studies the impact of HLA-matching grade in this context had not been taken into account. Taking advantage of a large multicentre study cohort of 1446 transplant pairs we were able to identify the 9/10 HLA-class I mismatched transplants as the decisive patient subgroup. We assume that, since activating signalling by KIR2DS1-C2 interaction is dominated by inhibiting KIR2DL1-C2[18;36], the effect of KIR2DS1-expressing donor NK-cells may be neutralized in 10/10 matched transplantations. In 9/10 matched transplant pairs, however, this domination could be shifted towards NK-cell activation by the stimulation of additional activating NK-receptors besides KIR, which enables KIR2DS1 (and maybe KIR2DS5) positive NK-cells to unfold their anti-leukemic reactivity.

There is some evidence for the potential of KIR2DS2-expressing NK-cells to control inflammatory processes[19], which would explain the positive influence of these cells on overall survival and disease free survival, but not on relapse incidence. Admittedly, the positive impact of KIR2DS2 in a patient group, which is negative for this receptors ligand seems to be hard to explain. However, the interaction potential of this receptor to ligands of the C1-group is yet not fully proven. Binding between KIR2DS2 and the C1-molecule HLA-C*16:01 but not with
further C1-ligands has been shown to be significant[19]. Additionally, there is evidence of peptide-dependant binding capacities between KIR2DS2 and genes of the HLA-A*11 group[60]. There may be additional ligands for this receptor which enable its activation, even in C1-negative patients.
Cooley et al. investigated the effect on donor KIR B-haplotype status on transplantation outcome in unrelated matched HSCT in AML patients with respect to the centromeric and telomeric A- and B haplotype motifs on the KIR locus[30]. According to their B-motif content, donors were grouped into "better/best" and "neutral", wherein the patients profited from transplantation with "better/best" donors. However, they could only show a significant effect...
of this model in C1-positive, but not C1-negative donors. We identified KIR2DS2 as the KIR with the most important effect on HSCT outcome in C1-negative patients with myeloid malignancies, yet the KIR B-motif model implies that KIR2DS2 may or may not be present in the “better/best” group, so we hypothesized that this model would blur the effects which we have found by analysing the activating KIRs separately. Indeed, the “better/best” donors showed no
beneficial effect on transplantation outcome in the C1-negative patients. Hence, the KIR B-motif model indeed showed a diminishing impact on C1-negative patients and therefore for this patient group complete KIR locus typing seems to bear no advantage. Instead, our results recommend donor typing for KIR2DS2 only (and possibly also for KIR2DS1).

Fig 20. Univariate TRM analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR3DS1 positive vs. KIR3DS1 negative donors. Solid black line: donor KIR3DS1 negative. Dashed orange line: donor KIR3DS1 positive. Donor KIR3DS1-negative (n = 72) vs. donor KIR3DS1-positive (n = 45), p = 0.35.

doi:10.1371/journal.pone.0169512.g020
In summary, our study shows that activating signals derived from KIR2DS1 and possibly KIR2DS5 can overcome the impaired NK-cell response in the C1-negative risk patient group, but also provoke the risk for TRM. These findings provide new insights for the selection of a suitable donor for the C1 negative risk patient group: for patients who are at high risk for relapse a KIR2DS1 donor positive may be an adequate choice, whereas a graft which is negative for this KIR may be an option when a high probability for treatment related complications is anticipated. The most important finding of our study, however, is the association of donor KIR2DS2 positivity with a better overall outcome after HSCT in the C1-negative risk patient group.

C1-negative patients with myeloid malignancies may therefore benefit from the inclusion of KIR2DS1- and more importantly KIR2DS2-genotyping in the search algorithm. Our findings certainly need to be confirmed by further studies in an independent cohort and also possibly by a prospective study, prior to conduct changes in the search algorithm.

Limitations

Our approach was to identify beneficial donor KIRs in the relatively small group of C1-negative patients (14% of all patients in our cohort). In this context, small subgroups were inevitable. However, while our study was limited by small sample sizes it nonetheless demonstrated statistically significant findings with a robust effect size.

Supporting Information

S1 Fig. Univariate OS analysis in C1-negative patients (missing C1 ligand) vs. C1-positive patients who were transplanted with KIR2DL2 or KIR2DL3 positive donors. Dashed red line: C1-negative patients (n = 200), fine red lines: corresponding confidence intervals. Solid black line: C1-positive patients (n = 1239), fine black lines: corresponding confidence intervals. p = 0.0014.

S2 Fig. Univariate DFS analysis in C1-negative patients (missing C1 ligand) vs. C1-positive patients who were transplanted with KIR2DL2 or KIR2DL3 positive donors. Dashed red line: C1-negative patients (n = 200), fine red lines: corresponding confidence intervals. Solid black line: C1-positive patients (n = 1239), fine black lines: corresponding confidence intervals. p = 0.006.
S3 Fig. Univariate RI analysis in C1-negative patients (missing C1 ligand) vs. C1-positive patients who were transplanted with KIR2DL2 or KIR2DL3 positive donors. Dashed red line: C1-negative patients (n = 200), fine red lines: corresponding confidence intervals. Solid black line: C1-positive patients (n = 1239), fine black lines: corresponding confidence intervals. p = 0.04. (TIFF)

S4 Fig. Univariate TRM analysis in C1-negative patients (missing C1 ligand) vs. C1-positive patients who were transplanted with KIR2DL2 or KIR2DL3 positive donors. Dashed red line: C1-negative patients (n = 200), fine red lines: corresponding confidence intervals. Solid black line: C1-positive patients (n = 1239), fine black lines: corresponding confidence intervals. p = 0.06. (TIFF)

S5 Fig. Univariate OS analysis in C2-negative (missing C2 ligand) vs. C2-positive patients who were transplanted with KIR2DL1-positive donors. Dashed red line: C2-negative patients (n = 823), fine red lines: corresponding confidence intervals. Solid black line: C2-positive patients (n = 558), fine black lines: corresponding confidence intervals. p = 0.08. (TIFF)

S6 Fig. Univariate DFS analysis in C2-negative (missing C2 ligand) vs. C2-positive patients who were transplanted with KIR2DL1-positive donors. Dashed red line: C2-negative patients (n = 823), fine red lines: corresponding confidence intervals. Solid black line: C2-positive patients (n = 558), fine black lines: corresponding confidence intervals. p = 0.11. (TIFF)

S7 Fig. Univariate RI analysis in C2-negative (missing C2 ligand) vs. C2-positive patients who were transplanted with KIR2DL1-positive donors. Dashed red line: C2-negative patients (n = 823), fine red lines: corresponding confidence intervals. Solid black line: C2-positive patients (n = 558), fine black lines: corresponding confidence intervals. p = 0.47. (TIFF)

S8 Fig. Univariate TRM analysis in C2-negative (missing C2 ligand) vs. C2-positive patients who were transplanted with KIR2DL1-positive donors. Dashed red line: C2-negative patients (n = 823), fine red lines: corresponding confidence intervals. Solid black line: C2-positive patients (n = 558), fine black lines: corresponding confidence intervals. p = 0.30. (TIFF)

S9 Fig. Univariate OS analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS2 positive donors vs. KIR2DS2 negative donors. Solid black line: donor KIR2DS2-negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR2DS2-positive, fine red lines: corresponding confidence intervals. 10/10 matched transplant pairs, donor KIR2DS2-negative (n = 32) vs. donor KIR2DS2-positive (n = 45), p = 0.86. (TIFF)

S10 Fig. Univariate OS analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS2 positive donors vs. KIR2DS2 negative donors. Solid black line: donor KIR2DS2-negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR2DS2-positive, fine red lines: corresponding confidence intervals. 9/10 matched transplant pairs, donor KIR2DS2-negative (n = 22) vs. donor KIR2DS2-positive
(n = 18), p = 0.04.

(TIFF)

S11 Fig. DFS analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS2 positive donors vs. KIR2DS2 negative donors. Solid black line: donor KIR2DS2-negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR2DS2-positive, fine red lines: corresponding confidence intervals. 10/10 matched transplant pairs, donor KIR2DS2-negative (n = 32) vs. donor KIR2DS2-positive (n = 45), p = 0.88.

(TIFF)

S12 Fig. DFS analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS2 positive donors vs. KIR2DS2 negative donors. Solid black line: donor KIR2DS2-negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR2DS2-positive, fine red lines: corresponding confidence intervals. 9/10 matched transplant pairs, donor KIR2DS2-negative (n = 22) vs. donor KIR2DS2-positive (n = 18), p = 0.05.

(TIFF)

S13 Fig. Univariate RI analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS1 positive vs. KIR2DS1 negative donors. Solid black line: donor KIR2DS1 negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR2DS1 positive, fine red lines: corresponding confidence intervals. Donor KIR2DS1-negative (n = 72) vs. donor KIR2DS1-positive (n = 45), p = 0.008.

(TIFF)

S14 Fig. Univariate RI analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS2 positive vs. KIR2DS2 negative donors. Solid black line: donor KIR2DS2 negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR2DS2 positive, fine red lines: corresponding confidence intervals. Donor KIR2DS2-negative (n = 54) vs. donor KIR2DS2-positive (n = 63), p = 0.33.

(TIFF)

S15 Fig. Univariate RI analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS5 positive vs. KIR2DS5 negative donors. Solid black line: donor KIR2DS5 negative, fine black lines: corresponding confidence intervals. Dashed red line: donor 5 positive, fine red lines: corresponding confidence intervals. Donor KIR2DS5-negative (n = 83) vs. donor KIR2DS5-positive (n = 34), p = 0.05.

(TIFF)

S16 Fig. Univariate RI analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR3DS1 positive vs. KIR3DS1 negative donors. Solid black line: donor KIR3DS1 negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR3DS1 positive, fine red lines: corresponding confidence intervals. Donor KIR3DS1-negative (n = 72) vs. donor KIR3DS1-positive (n = 45), p = 0.06.

(TIFF)

S17 Fig. Univariate TRM analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS1 positive vs. KIR2DS1 negative donors. Solid black line: donor KIR2DS1 negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR2DS1 positive, fine red lines: corresponding confidence intervals. Donor
KIR2DS1-negative (n = 72) vs. donor KIR2DS1-positive (n = 45), p = 0.06.

S18 Fig. Univariate TRM analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS5 positive vs. KIR2DS5 negative donors. Solid black line: donor KIR2DS5 negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR2DS5 positive, fine red lines: corresponding confidence intervals. Donor KIR2DS5-negative (n = 83) vs. donor KIR2DS5-positive (n = 34), p = 0.45.

S19 Fig. Univariate TRM analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR2DS2 positive vs. KIR2DS2 negative donors. Solid black line: donor KIR2DS2 negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR2DS2 positive, fine red lines: corresponding confidence intervals. Donor KIR2DS2-negative (n = 54) vs. donor KIR2DS2-positive (n = 63), p = 0.001.

S20 Fig. Univariate TRM analysis in C1-negative patients with myeloid malignancies who were transplanted with KIR3DS1 positive vs. KIR3DS1 negative donors. Solid black line: donor KIR3DS1 negative, fine black lines: corresponding confidence intervals. Dashed red line: donor KIR3DS1 positive, fine red lines: corresponding confidence intervals. Donor KIR3DS1-negative (n = 72) vs. donor KIR3DS1-positive (n = 45), p = 0.35.

Acknowledgments
This work was supported by the Deutsche José Carreras Leukämie-Stiftung e.V. (Grant No. DJCLS 11/10), and the German Red Cross Blood Transfusion Service, Baden-Wuerttemberg–Hessen.

We are grateful to the following colleagues for contribution of their patients:

- Department of Hematology/Oncology, University of Leipzig, Germany: Niederwieser Dietger, Bühner Alexander
- Department of Internal Medicine III, University of Ulm, Germany: Bunjes Donald, Missel Lucia
- Hematology, Oncology and Pneumology, University Medical Center Mainz, Germany: Wagner Eva, Waldeck Birgit
- Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, University of Kiel, Germany: Gramatzki Martin, Helweg Marianne
• Centre for Bone Marrow and Blood Stem Cell Transplantation, Deutsche Klinik für Diagnostik, Wiesbaden, Germany: Stuhler Gernot, Eichler Susanne

• Hematology/Oncology Department, Charité Campus Virchow Berlin, Germany: Arnold Renate

• Department of Medicine II, University Hospital Würzburg, Germany: Einsele Hermann, Grigoleit Götz Ulrich, Bönig Heidrun

• Department of Hematology/Oncology, Georg-August-University Göttingen, Germany: Trümper Lorenz, Gerald Wulf

• Department Internal Medicine I, Universitätsklinikum des Saarlandes, Homburg, Germany: Pfreundschuh Michael, Martin Renate

• Department of Hematology/Oncology, Asklepios Klinik St. Georg, Hamburg, Germany: Dingeldein Susanne, Zeis Matthias

• Medical Clinic 5, Hematology and Oncology, Klinikum Nuremberg, Nuremberg, Germany: Schäfer-Eckart Kerstin

• Medical Clinic III, Hematology and Oncology, University Clinic r.d.Isar, Munich, Germany: Peschel Christian

• Medical Clinic 5, Hematology and Oncology, University of Erlangen-Nuremberg, Germany: Mackensen Andreas

• Hematology/Oncology Department, Robert-Bosch Clinic, Stuttgart, Germany: Aulitzky Walter Erich, Kaufmann Martin, Eier Nicole

• Hematology/Oncology Department, University of Rostock, Germany: Freitag Sebastian

• Hematology/Oncology Department, Clinic Oldenburg, Germany: Casper Jochen

• Clinic for Stem Cell Transplantation, University Medical Center Hamburg- Eppendorf, Germany: Zander Axel, Kasper Anja

• Department of Hematology/Oncology, University of Regensburg, Germany: Herr Wolfgang, Holler Ernst

• Department of Hematology/Oncology, Evangelisches KKH Essen-Werden, Germany: Wattd Mohammed, Manicone Julia

• Hematology/Oncology Department, Clinic Bremen-Mitte, Germany: Hertenstein Bernd

• Hematology/Oncology Department, Clinic Idar-Oberstein, Germany: Gregor Sebastian

• Medical Clinic II, Hematology and Oncology, J.W.-Goethe-University, Frankfurt/Main, Germany: Martin Hans, Serve Hubert

• Department of Oncology/Hematology, Martin Luther University Halle, Germany: Müller-Tidow Carsten, Körholz Dieter, Bach Jana

• Hematology/Oncology Department, Clinic Karlsruhe, Germany: Ringhoffer Mark, Schiefer Julie

• Department of Hematology/Oncology, University Hospital Schleswig-Holstein, Lübeck, Germany: Biersack Harald, Marx Rudina
• Hematology/Oncology Department, University Hospital Mannheim, Germany: Klein Stefan, Folz Christine

• Transplantation Immunology Department, German Red Cross Blood Transfusion Service, Baden-Wuerttemberg–Hessen, Ulm, Germany and Institute of Transfusion Medicine, University of Ulm, Germany: Marlene Fischer, Sabine Simon, Renate Hanold, Martina Baumann

Ethics Statement
The study was approved by the ethical review board of the University of Ulm (project number 263/09).

Author Contributions
Conceptualization: CN.
Data curation: DF.
Formal analysis: CN.
Funding acquisition: DF.
Investigation: CN.
Methodology: CN DF.
Project administration: JM.
Resources: DN DB GW MP EW GS HE.
Supervision: JM.
Writing – original draft: CN DF JM.
Writing – review & editing: DF DN DB CT GW MP EW GS HS JM.

References
1. Barrett AJ, Battiwalla M. Relapse after allogeneic stem cell transplantation. Expert Rev Hematol 2010 Aug; 3(4):429–41. doi: 10.1586/ehm.10.32 PMID: 21083034
2. Zinkernagel RM, Bachmann MF, Kundig TM, Oehen S, Pircher H, Hengartner H. On immunological memory. Annu Rev Immunol 1996; 14:333–67. doi: 10.1146/annurev.immunol.14.1.333 PMID: 8717518
3. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990 Feb 1; 75(3):555–62. PMID: 2297567
4. Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev 2010 Nov; 36(7):528–38. doi: 10.1016/j.ctrv.2010.03.004 PMID: 20381970
5. Riemersma SA, Jordanova ES, Schop RF, Philippo K, Looijenga LH, Schuuring E, et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000 Nov 15; 96(10):3569–77. PMID: 11071656
6. Demanet C, Mulder A, Deneyes V, Worsham MJ, Maes P, Claas FH, et al. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 2004 Apr 15; 103(8):3122–30. doi: 10.1182/blood-2003-07-2500 PMID: 15070694
7. Brouwer RE, van der Heiden P, Schreuder GM, Mulder A, Datema G, Anholt JD, et al. Loss or downregulation of HLA class I expression at the allotypic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon. Hum Immunol 2002 Mar; 63(3):200–10. PMID: 11872238
8. Ruggeri L, Capanni M, Casucci M, Volpi I, Tosti A, Perruccio K, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999 Jul 1; 94(1):333–9. PMID: 10381530

9. Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest 1998 May 1; 101(9):1835–42. doi: 10.1172/JCI11268 PMID: 9576746

10. Vitale M, Sivori S, Pende D, Augugliaro R, di DC, Amoroso A, et al. Physical and functional independency of p70 and p58 natural killer (NK) cell receptors for HLA class I: their role in the definition of different groups of alloreactive NK cell clones. Proc Natl Acad Sci U S A 1996 Feb 20; 93(4):1453–7. PMID: 8643653

11. Moretta A, Bottino C, Pende D, Tripodi G, Tambussi G, Viale O, et al. Identification of four subsets of human CD3-CD16+ natural killer (NK) cells by the expression of clonally distributed functional surface molecules: correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990 Dec 1; 172(6):1589–98. PMID: 2147946

12. Wagtmann N, Rajagopalan S, Winter CC, Peruzzi M, Long EO. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 1995 Dec; 3(6):801–9. PMID: 8777725

13. Middleton D, Gonzalez F. The extensive polymorphism of KIR genes. Immunology 2010 Jan; 129(1):8–19. doi: 10.1111/j.1365-2567.2009.03208.x PMID: 20028428

14. Robinson J, Halliwell JA, Hayhurst JD, Flicek P, Parham P, Marsh SG. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 2015 Jan 28; 43(Database issue):D423–D431. doi: 10.1093/nar/gku1161 PMID: 25414341

15. Uhrberg M, Valiante NM, Shum BP, Shilling HG, Lienert-Woldebach K, Corliss B, et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997 Dec; 7(6):753–63. PMID: 9430221

16. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005 Mar; 5(3):201–14. doi: 10.1038/nri1570 PMID: 15719024

17. Biassoni R, Falco M, Cambiaggi A, Costa P, Verdiani S, Pende D, et al. Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by “group 2” or “group 1” NK clones. J Exp Med 1995 Aug 1; 182(2):605–9. PMID: 7629517

18. David G, Djoud Z, Willem C, Legrand N, Rettman P, Gagne K, et al. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR)2DL2 and KIR2DL3 and restricted C1 SPECIFICITY of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation. J Immunol 2013 Nov 1; 191(9):4778–88. doi: 10.4049/jimmunol.1301580 PMID: 24078689

19. Moesta AK, Parham P. Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C. KIR2DS2, KIR2DL2, and KIR2DL3. Front Immunol 2012; 3:336. doi: 10.3389/fimmu.2012.00336 PMID: 23189078

20. Ruggeri L, Capanni M, Mancusi A, Martelli MF, Velardi A. The impact of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transpl Immunol 2005 Aug; 14(3–4):203–6. doi: 10.1016/j.trim.2005.03.008 PMID: 15982564

21. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001; 19:197–223. doi: 10.1146/annurev.immunol.19.1.197 PMID: 11244035

22. Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 1990 Jul; 11(7):237–44. PMID: 2201309

23. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity on allogeneic hematopoietic transplantation. Transpl Immunol 2005 Aug; 14(3–4):203–6. doi: 10.1016/j.trim.2005.03.008 PMID: 15982564

24. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, et al. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant 2006 Aug; 12(8):876–84. doi: 10.1016/j.bbmt.2006.05.007 PMID: 16684058

25. Morishima Y, Yabe T, Matsuou K, Kashihara K, Inoko H, Saji H, et al. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T-cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007 Mar; 13(3):315–28. doi: 10.1016/j.bbmt.2006.10.027 PMID: 17317585
26. Davies SM, Ruggieri L, DeFor T, Wagner JE, Weisdorf DJ, Miller JS, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood 2002 Nov 15; 100(10):3825–7. doi: 10.1182/blood-2002-04-1197 PMID: 12393440

27. Fischer JC, Kobbe G, Enczmann J, Haas R, Uhrberg M. The impact of HLA-C matching depends on the C1/C2 KIR ligand status in unrelated hematopoietic stem cell transplantation. Immunogenetics 2012 Dec; 64(12):879–85. doi: 10.1007/s00251-012-0648-7 PMID: 22923051

28. Cooley S, Trachtenberg E, Bergemann TL, Saeurn K, Klein J, Le CT, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009 Jan 15; 113(3):726–32. doi: 10.1182/blood-2008-07-171926 PMID: 18945962

29. Zhou H, Bao X, Wu X, Tang X, Wang M, Wu D, et al. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014 Jan; 20(1):98–105. PMID: 24516895

30. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Marsh SG, et al. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 2014 May 15; 192(10):4592–600. doi: 10.4049/jimmunol.13002517 PMID: 24748496

31. Knorr DA, Wang H, Aurora M, MacMillan ML, Holton SG, Bergerson R, et al. Loss of T Follicular Helper Cells In the Peripheral Blood Of Patients With Chronic Graft vs. Host Disease. Biol Blood Marrow Transplant 2016 Jan 12.

32. Fürst D, Zolliker C, Müller C, Niederwieser D, Bunjes DW, Wagner E, et al. Donors with KIR-Bx Haplotypes Improve Outcome of Unrelated Hematopoietic Stem Cell Transplantation for Recipients with a Myeloid Malignant Disease and a C1 Ligand Phenotype. Biol Blood Marrow Transplant 2015 Feb; 21(2):S31.

33. Bonagura VR, Du Z, Ashouri E, Luo L, Hatam LJ, DeVoti JA, et al. Activating KIR2DS1 receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis. Hum Immunol 2010 Feb; 71(2):212–9. doi: 10.1016/j.humimm.2009.10.009 PMID: 19861144

34. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007 Nov 26; 204(12):3027–36. doi: 10.1084/jem.20070695 PMID: 18025129

35. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004 Aug 6; 305(5685):872–4. doi: 10.1126/science.1097670 PMID: 15297676

36. Sivori S, Carlomagno S, Falco M, Romeo E, Moretta L, Moretta A. Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: implications in haploidentical HSCT. Blood 2011 Apr 21; 117(16):4284–92. doi: 10.1182/blood-2010-10-316125 PMID: 21355085

37. Venstrom JM, Pittari G, Gooley TA, Spellman S, Haagenson M, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med 2012 Aug 30; 367(9):805–16. doi: 10.1056/NEJMoa1200503 PMID: 22931314

38. Iacobelli S. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2013 Mar; 48 Suppl 1:S1–37.

39. EBMT.org [Internet]. European Group for Blood and Marrow Transplantation. MED-AB forms manual. A guide to the completion of the EBMT HSCT MED-AB forms. appendix iii. [Updated 2015 August 18; cited 2015 September 12]. Available from: http://www.ebmt.org/Contents/Data-Management/Registrystructure/MED-ABdatacollectionforms/Documents/MED-ABFormsManual.pdf.

40. Baccalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009 Dec; 15(12):1628–33. doi: 10.1016/j.bbmt.2009.07.004 PMID: 19896087

41. bioinformatics.bethematchclinical.org [Internet]. National Marrow Donor Program. NMDP Policy for HLA Confirmatory Typing Requirements for Unrelated Adult Donors and Patients. [Updated 2015 January; cited 2015 September 12]. Available from: https://bioinformatics.bethematchclinical.org/WorkArea/DownloadAsset.aspx?pdfId=10528

42. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de WT, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009 Oct 15; 115(20):4715–26. doi: 10.1002/cncr.24531 PMID: 19642176

43. EBMT.org [Internet]. Labopin M, Iacobelli S. Statistical guidelines for EBMT. [Updated October 2003; cited 2015 September 12]. Available from: http://www.ebmt.org/1WhatsisEBMT/Op_Manual/OPMAN _StatGuidelines_oct2003.pdf.
44. Glidden DV, Vittinghoff E. Modelling clustered survival data from multicentre clinical trials. Stat Med 2004 Feb 15; 23(3):369–88. doi: 10.1002/sim.1599 PMID: 14748034

45. CRAN.R-project.org [Internet]. Therneau T. A Package for Survival Analysis in S. R package version 2.38. [updated 2015 July 02; cited 2015 September 12]. Available from: http://CRAN.R-project.org/package=survival

46. Gratwohl A. The EBMTRisk score. Bone Marrow Transplant 2012 Jun; 47(6):749–56. doi: 10.1038/bmt.2011.110 PMID: 21643021

47. Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011 Jan; 39(Database issue):D913–D919. doi: 10.1093/nar/gkq1128 PMID: 21062830

48. Fischer JC, Ottinger H, Ferencik S, Sribar M, Punzel M, Beelen DW, et al. Relevance of C1 and C2 epitopes for hematopoietic stem cell transplantation: role for sequential acquisition of HLA-C-specific inhibitory killer Ig-like receptor. J Immunol 2007 Mar 15; 178(6):3918–23. PMID: 17339492

49. Giebel S, Locatelli F, Wojnar J, Velardi A, Mina T, Giorgiani G, et al. Homozygosity for human leucocyte antigen-C ligands of KIR2DL1 is associated with increased risk of relapse after human leucocyte antigen-C-matched unrelated donor haematopoietic stem cell transplantation. Br J Haematol 2005 Nov; 131(4):483–6. doi: 10.1111/j.1365-2141.2005.05797.x PMID: 16281939

50. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005 Jun 15; 105(12):4878–84. doi: 10.1182/blood-2004-12-4825 PMID: 15731175

51. Ahlenstiel G, Martin MP, Gao X, Carrington M, Rehermann B. Distinct KIR/HLA compound genotypes affect the kinetics of antiviral natural killer cell responses. J Clin Invest 2008 Mar; 118(3):1017–26. doi: 10.1172/JCI32400 PMID: 18246204

52. Wilson MJ, Torkar M, Trowsdale J. Genomic organization of a human killer cell inhibitory receptor gene. Tissue Antigens 1997 Jun; 49(6):574–9. PMID: 9234478

53. Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O’Reilly RJ, et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009 Apr 16; 113(16):3875–84. doi: 10.1182/blood-2008-09-177055 PMID: 19179302

54. Jamil KM, Khakoo SI. KIR/HLA interactions and pathogen immunity. J Biomed Biotechnol 2011; 2011:298348. doi: 10.1155/2011/298348 PMID: 21629750

55. Vales-Gomez M, Reyburn H, Storminger J. Interaction between the human NK receptors and their ligands. Crit Rev Immunol 2000; 20(3):223–44. PMID: 10968372

56. Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implications of HL A-G. Leukemia 2008 May; 22(5):998–1006. doi: 10.1038/leu.2008.15 PMID: 18288133

57. Zingoni A, Somasse T, Cocks BG, Tanaka Y, Santoni A, Lanier LL. NK cell regulation of T cell-mediated responses. Mol Immunol 2005 Feb; 42(4):451–4. doi: 10.1016/j.molimm.2004.07.025 PMID: 15607797

58. Tittle TV, Weinberg AD, Steinkeler CN, Maziarz RT. Expression of the T-cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease. Blood 1997 Jun 15; 89(12):4652–8. PMID: 9192792

59. Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. Kir2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J Immunol 2007 Jul 15; 179(2):854–68. PMID: 17617576

60. Liu J, Xiao Z, Ko HL, Shen M, Ren EC. Activating killer cell immunoglobulin-like receptor 2DS2 binds to HLA-A*11. Proc Natl Acad Sci U S A 2014 Feb 18; 111(7):2662–7. doi: 10.1073/pnas.1322052111 PMID: 24550293